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Abstract
Background: Parathyroid carcinoma is a rare cause of primary hyperparathyroidism and may be
associated with significant disease related morbidity and mortality. Preoperative diagnosis remains
a challenge, which may jeopardize appropriate and successful patient treatment.
Case presentation: We report a case of parathyroid carcinoma diagnosed in a 60-year-old
woman that presented with a tender nodule located at the left lower thyroid pole and had been
present for several years. Ultrasound examination revealed a 2.7 × 1.6 × 2.7 cm mass within the
lower left lobe of the thyroid with cystic and solid areas. Lab measurement of the intact PTH level
revealed it to be three times the upper limit of normal and the serum calcium level was within
normal limits. A left thyroid lobectomy and isthmusectomy was carried out. Histopathological
evaluation was diagnostic for a parathyroid carcinoma. At greater than two years of follow-up, the
patient has had no evidence of disease recurrence and her serum PTH and calcium levels have
remained within normal.
Conclusion: Parathyroid carcinoma is a rare endocrine tumor which must be considered in the
differential diagnosis of a nodular thyroid mass. En bloc resection remains the treatment of choice
for this malignancy. Disease prognosis is influenced by the extent of the initial resection, the
presence of metastases, and adequate long-term follow-up.
Background
Parathyroid carcinoma (PC) is responsible for fewer than
1% of cases of primary hyperparathyroidism [1]. The
majority of patients with PC present in their fifties, and
unlike parathyroid adenoma or hyperplasia which pre-
dominantly effect women, PC appears to be equally dis-
tributed between the genders [1]. Patients may present
with one or more characteristic features of PC, which
include severe symptoms of primary hyperparathyroidism
and significantly elevated serum PTH (Table 1). Parathy-
roid carcinoma may arise as a sporadic disease, with
familial hyperparathyroidism [2], with hyperparathy-
roidism-jaw tumour syndrome [3], or with multiple endo-
crine neoplasia type 1 (MEN-1) [4].
In this article we report on a case of PC that presented as
a tender thyroid mass. It was resected and diagnosed post-
operatively as PC. The patient has remained disease free
for greater than two years postoperatively.
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Case presentation
A 60-year-old woman was referred for evaluation of a ten-
der nodule in the left lobe of the thyroid. She had no prior
history of head and neck radiation and no family history
of thyroid or parathyroid disease. The patient had noted
little change in lesion size but persistent pain, aggravated
by talking, which was troublesome for her. She did not
have any complaints of voice change. She had initially
been investigated 5 years earlier with complaints of pain
radiating over the left side of her face. At that time a small
firm nodule in the left thyroid lobe was discovered and a
needle biopsy found no evidence of malignancy. At that
time it was diagnosed as a benign nodular goiter and
observation was recommended.
An ultrasound identified a left lower thyroid lobe mass
measuring 2.7 × 1.6 × 2.7 cm with cystic and solid compo-
nents. Her serum ionized calcium level was normal and
her intact PTH was elevated to three times the upper limit
of normal. Due to ongoing facial pain a left thyroid lobec-
tomy and isthmusectomy was carried out. Intraopera-
tively, a firm multinodular left thyroid lobe was
appreciated. There were no abnormal central compart-
ment lymph nodes identified or removed at surgery.
Pathological examination of the specimen revealed a
large, yellowish tumor measuring 2.7 × 2.0 × 2.0 cm that
was pushing into the left thyroid lobe, but separated from
it by a fibrous capsule (Figure 1). The mass was noted to
be composed of monomorphous parathyroid cells with-
out significant necrosis or mitotic activity. There was inva-
sion into the thyroid capsule and into adjacent fatty
tissue. No vascular invasion was noted (Figure 2). A cystic
goiter was also noted in the left thyroid lobe. Further
immunohistochemical studies found the tumour did not
express: Thyroid Transcription Factor – 1, Calcitonin, and
carcinoembryonic antigen (CEA), but did express Chro-
magranin, Synaptophysin, Bcl -2 and Cytokeratin 7.
Postoperatively the patient's parathyroid hormone nor-
malized and her ionized serum calcium level remained
within normal limits. Her postoperative course was une-
ventful and she has remained disease free greater than 27
months postoperatively.
Discussion
PC is a rare cause of primary hyperparathyroidism. Its rar-
ity makes preoperative diagnosis difficult and much of
our current knowledge of this cancer is derived from ret-
rospective case studies. In the vast majority of patients, PC
tends to be a functional malignancy. Non-functional par-
athyroid cancers are especially uncommon, accounting
for approximately 1.9% of parathyroid tumors and repre-
sent a [1] prognostic indicator of poor outcome. Patients
with non-functional tumors tend to present later in their
disease course, and it is speculated that these cancers may
be more aggressive. At presentation approximately 40% of
PC patients will have profound hypercalcemia and a pal-
pable neck mass [1]. PC rarely presents with cervical,
mediastinal or distant metastatisis. Koea et al, [1] reported
that of 301 PC patients, 10 patients (2%) had regional
nodal metastasis at initial presentation and 9 [2] patients
Table 1: Clinical distinctions between primary hyperthyroidism and parathyroid carcinoma. Adapted from [38].
Parathyroid carcinoma Primary hyperparathyroidism
Palpable neck mass 50% <10%
Hypercalcemia (normal = 8.5–9.9 mg/dL) > 14 mg/dL 11–12 mg/dL
↑ PTH (normal = 10–65 pg/mL) 3–10× normal 2× normal
Renal impairment (nephrilithiasis, nephrocalcinosis, impaired GFR) 32–84% <20%
Skeletal abnormalities (osteitis fibrosa cystica, diffuse spinal osteopenia, 
subperiosteal bone resorption, salt-and-pepper skull)
44–91% <10%
Parathyroid carcinoma show mushrooming invasion through  capsule into the surrounding fat Figure 2
Parathyroid carcinoma show mushrooming invasion through 
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(2%) were diagnosed with distant metastasis to lung or
bone at their initial presentation.
Interestingly, several reports have noted that the lower
parathyroid glands appear to have an increased incidence
of PC [1,5-7]. The lower parathyroid glands are derived
from the third branchial arch, a different embryologic ori-
gin then the superior thyroid glands, which are derived
from fourth branchial arch. It is unknown why the infe-
rior parathyroid glands appear to have an increased pre-
disposition for carcinoma development.
While the etiology of PC remains poorly defined, recent
studies of its molecular pathogenesis have implicated sev-
eral genes. These genes include: cyclin D1, [8], p53 [9] and
the retinoblastoma tumour suppressor gene [10]. Moreo-
ver, individuals with familial hyperparathyroidism, MEN-
2 [4], and hyperparathyroidism-jaw tumour syndrome [3]
appear to have an increased predisposition for the devel-
opment of PC.
Intraoperatively PC presents as a hard, lobulated mass
that invades the thyroid [1,11-13]. The neoplasm fre-
quently is found to adhere to surrounding structures
including the thyroid gland, the strap muscles, the recur-
rent laryngeal nerve, esophagus, and trachea [1,11-13].
The diagnosis of parathyroid carcinoma is based on the
histopathological criteria established by Shantz and Cas-
tleman in 1973 [14]. These histopathologic criteria
include: the presence of a fibrous capsule or fibrous
trabeculae, trabecular or rosette-like cellular architecture,
the presence of mitotic figures, and the presence of capsu-
lar or vascular invasion. These criteria have been chal-
lenged by McKeown et al [15], who noted that it is critical
to differentiate between mitotic activity in tumor paren-
chymal cells versus endothelial cells. They further sug-
gested that cellular pleomorphism and atypia are
unreliable indicators of malignancy in this endocrine can-
cer. In 1993 Bondeson and colleagues [16] addressed this
controversy by careful analysis of 56 histopathological
specimens of metastatic PC. They found that mitotic activ-
ity in these carcinomas was highly variable with half of
cases had mitotic rates comparable to benign parathyroid
lesions. Further, while fibrosis, usually with the capsule,
was observed in 80% of these carcinomas, the authors
reported that a trabecular architecture pattern was not
diagnostic of PC, as it was also observed in parathyroid
adenomas and hyperplasia.
Recent immunohistochemical studies have attempted to
distinguish benign from malignant parathyroid neo-
plasms by utilizing immunohistochemical markers. One
study [17] revealed that 76% of the patients with typical
parathyroid adenoma had a phenotype of p27(+)bcl-2(-
)Ki-67(-)mdm2(+) compared to none of those patients
diagnosed with PC. Other studies have found that more
that half of patients diagnosed with PC showed one of
three molecular phenotypes: p27(+)bcl-2(-)Ki-
67(+)mdm2(-) (9%), p27(-)bcl-2(-) Ki-67(-)mdm2(-)
(27%), and p27(-)bcl-2(+)Ki-67(+)mdm2(-) (18%).
None of these phenotypes were observed in patients diag-
nosed with parathyroid adenomas. These studies demon-
strated the potential clinical utility of
immunohistochemical markers in differentiating benign
versus malignant parathyroid disease. However, it is still
generally agreed that that invasion into surrounding tis-
sues, the presence of a fibrotic capsule, and nuclear atypia
remain the most accurate predictors of malignant histol-
ogy in parathyroid neoplasms [1].
Currently the gold standard for the treatment of parathy-
roid carcinoma is en bloc surgical resection. Surgery may
require thyroid lobectomy, isthmusectomy and possibly
central neck nodal dissection. Removal of all tissue to
which tumour is adherent, including the recurrent laryn-
geal nerve, trachea, or oesophagus, may be necessary
[1,7,18,19]. PC patients have the highest chance of cure if
en block resection is carried out at their initial operation.
Controversy exists as to whether the patient in whom
malignancy is recognized after tumorectomy requires
reoperation with resection of all structures adjacent to
where the tumour was originally located. Some investiga-
tors have suggested that in these cases en bloc resection
may be postponed until tumour recurrence is recognized
by rising calcium levels [20].
Gross appearance of parathyroid tumour and thyroid lobe Figure 1
Gross appearance of parathyroid tumour and thyroid lobe.World Journal of Surgical Oncology 2006, 4:10 http://www.wjso.com/content/4/1/10
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Intraoperative PTH (IPTH) measurement is an emerging
technique for optimizing tumour removal while minimiz-
ing the invasiveness of parathyroid surgery. Multiple stud-
ies have investigated its use in the surgical management of
primary hyperparathyroidism but its role in the manage-
ment of PC remains unclear. Current literature, however,
suggests that with conservative PC resection is associated
with a significant risk of capsule rupture and subsequent
local dissemination of the tumour [20]. There have also
been several reports of false-positive phenomena in cases
of multiple gland pathology including double adenomas,
and combination adenoma and hyperplasia, wherein the
PTH level decreases to within the normal range, but
begins to increase post-operatively [21,22]. It can be pos-
tulated that IPTH measurement may be of limited appli-
cation to PC when metastases are present.
Historically, radiotherapy and/or chemotherapy have had
little role in the treatment of PC and have generally been
utilized for palliation of patients who are not candidates
for surgery [5,14,23-25]. Several recent studies, have sug-
gested that adjuvant radiotherapy may lengthen the dis-
ease free survival period in PC patients [26-30].
Chemotherapy has had a limited role in the treatment of
PC. Several regimens (nitrogen mustard; vincristine,
cyclophosphamide and actinomycin D; adriamycin,
cyclophosphamide, and 5-fluorouracil; and adriamycin
alone) have been unsuccessful [23,31,32]. Partial
responses to dacarbazine, both alone and in combination
with other drugs, have been reported [33-36]. Several case
reports have documented rare responses to other chemo-
therapy regimes [25,37].
Disease recurrence of PC is common and reported rates
range from 33% to 78% [6,12,25,38,39]. It has been sug-
gested that the variability in these estimates are due to the
application of different diagnostic criteria in multiple
small retrospective studies [18]. Elevated serum PTH and
calcium levels are present in persistent or recurrent disease
in greater than half of patients with parathyroid carci-
noma who are not cured by their initial treatment [12].
Most PC recurrences occur 2 to 3 years after surgery [39],
although recurrence has been reported up to 23 years after
an initial surgical resection [12]. It is also important to rec-
ognize that patients may have non-functioning metastatic
PC. Approximately 25% of PC patients develop distant
metastasis during follow-up, most commonly to the lungs
and bones, and less frequently to the liver [12,13]. Data
from a United States National Cancer Database report
suggests the five and ten year survival rates for parathyroid
carcinoma are 85% and 49%, respectively [40].
Patients with parathyroid carcinoma more commonly die
from refractory hypercalcemia rather than the tumour
burden itself [25, 41]. Therefore an important aspect of
medical management of these patients relates to the treat-
ment of hypercalcemia. This includes potentiation of cal-
ciuresis with saline infusion and loop diuretics [42], as
well as application of agents that interfere with osteoclast-
mediated bone reabsorption. These include several
groups of drugs that include: bisphosphonates, plicamy-
cin (mithramycin), calcitonin and calcimimetics [25, 41,
42, 43, 44].
Conclusion
PC is a rare ensdocrine cancer with an insidious clinical
course that is often misdiagnosed as primary hyperparath-
yroidism secondary to parathyroid adenoma or hyperpla-
sia. Most commonly PC patients present with a neck mass
and signs of severe hypercalcemia with metabolic bone
disease and renal failure. As was the case for our patient,
normocalcemia at presentation is unusual. Incomplete
tumor resection leads to recurrence and mortality rates
approaching 50%. Thus, preoperatively differentiating
between benign and malignant parathyroid neoplasms,
though a challenge, is important, and en bloc tumor resec-
tion offers these patients the best chance for cure.
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